The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Ibrutinib updates from ASH 2016
Peter Hillmen, MBChb, PhD, FRCP, FRCPath of St. James’ University Hospital, Leeds, UK discusses the update on ibrutinib for chronic lymphocytic leukemia (CLL) presented at the 2016 Annual Meeting of the American Society of Hematology, held in San Diego, CA. The RESONATE-2 trial looked at frontline ibrutinib compared with chlorambucil (NCT01722487). Prof. Hillmen explains that the updated data are looking very positive with patients randomized to ibrutinib having good progression-free survival (PFS). Further, the five-year update of a small Phase II trial of single agent ibrutinib also shows durable remissions (NCT01105247).
